Mean platelet volume and platelet distribution width serve as prognostic biomarkers in skull base chordoma: a retrospective study

Abstract

Background Increasing studies have demonstrated that activated platelets play an essential role in tumour progression. However, the level and prognostic role of platelet indices in chordoma patients remain unclear. The aim of the current study was to characterize the prognostic performance of platelet count (PLT), mean platelet volume (MPV) and platelet distribution width (PDW) in skull base chordoma patients. Methods 187 primary skull base chordoma patients between January 2008 and September 2014 were enrolled in this retrospective study. The optimal cut-off values were determined by X-tile software, and the correlations between PLT, MPV, PDW and clinicopathological features were further analysed. Kaplan-Meier curve and Cox regression analysis were used for survival analysis. Results The values of preoperative PTL, MPV and PDW ranged from 104 to 501 × 109/L, 6.7 to 14.2 fl, and 7.8 to 26.2%, respectively. Elevated PLT was associated with larger tumour volume (p = 0.002). Kaplan-Meier survival analysis revealed that increased MPV and PDW were associated with shorter overall survival (p = 0.022 and 0.008, respectively). Importantly, multivariate Cox analysis demonstrated that elevated PDW was an independent unfavourable predictive factor for overall survival (hazard ratio (HR), 2.154, 95% confidence interval (CI), 1.258–3.688, p = 0.005). Conclusions Our data show that elevated MPV and PDW are associated with poor outcomes in skull base chordoma and that PDW may be helpful to identify patients with high risk.

Development and validation of nomogram based on a novel platelet index score to predict prognosis in patients with renal cell carcinoma

“…Although our study failed to show the prognostic value of MPV, the PDW was another novel biomarker in predicting prognosis for RCC patients, which has not been investigated before. Several studies have shown high PDW was associated with poor survival in hepatocellular, breast cancers as well as skull base chordoma [31][32][33]. However, low PDW has also been reported that correlated with worse survival in endometrial, esophageal, gastric cancers [34][35][36], which consistent with our study result that low PDW was related to shorter PFS in RCC patients.…”

High Red Cell Distribution Width Independently Predicts Adverse Survival in Patients with Newly Diagnosed Skull Base Chordoma

“…Overall, 187 skull base chordoma patients (98 males and 89 females) with a mean age of 40.1 (SD, 15.3) years were included in current retrospective research. 22 Of these patients, 126 (67.4%) patients had the classical pathological type of chordoma, and the remaining 61 (32.6%) patients got chondroid chordoma, no dedifferentiated chordoma was observed. 4 There were 57 (30.5%) patients with soft tumors and 130 (69.5%) patients who harbored moderate or tough tumors.…”

“…Finally, 187 patients with primary skull base chordoma were enrolled, and this cohort has been detailed in our previous study. 22 …”

Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5

“…The clinical information (age, classified by 55 years; gender; tumour volume, classified by 20 cm 3 ; blood supply, abundant (tumour resection surface with a tendency to bleed and is hard to aspirate clearly), poor (limited bleeding that is easy to aspirate clearly) and moderate (between poor and abundant); texture, classified as hard (tumours could hardly be excised without scissor or punch forceps), soft (tumours could be easily suctioned when using the aspirator) and moderate (between hard and soft); etc.) of the 84 patients was reviewed as our previous study reported and is detailed in Table 4,29,30 . IHC was performed using the Leica Bond III automated system as we have described previously 2 .…”

“…of the 84 patients was reviewed as our previous study reported and is detailed in Table S4 . 4 , 29 , 30 IHC was performed using the Leica Bond III automated system as we have described previously. 2 Primary antibody against ATG5 (sc‐133158, 1:50; Santa Cruz Biotechnology) was used for IHC of chordoma specimens.…”